Tudor Investment Corp ET AL increased its position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 33.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 35,387 shares of the company’s stock after buying an additional 8,960 shares during the period. Tudor Investment Corp ET AL owned approximately 0.08% of Amphastar Pharmaceuticals worth $513,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Vanguard Group Inc. raised its position in Amphastar Pharmaceuticals by 0.4% in the first quarter. Vanguard Group Inc. now owns 2,179,764 shares of the company’s stock valued at $31,607,000 after buying an additional 8,744 shares during the last quarter. State Street Corp raised its position in Amphastar Pharmaceuticals by 11.1% in the first quarter. State Street Corp now owns 1,062,439 shares of the company’s stock valued at $15,406,000 after buying an additional 106,448 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Amphastar Pharmaceuticals by 32.5% in the first quarter. Dimensional Fund Advisors LP now owns 1,061,188 shares of the company’s stock valued at $15,388,000 after buying an additional 260,288 shares during the last quarter. Rothschild Asset Management Inc. purchased a new position in Amphastar Pharmaceuticals during the first quarter valued at $9,056,000. Finally, Teachers Advisors LLC raised its position in Amphastar Pharmaceuticals by 0.3% in the fourth quarter. Teachers Advisors LLC now owns 542,953 shares of the company’s stock valued at $10,001,000 after buying an additional 1,693 shares during the last quarter. 45.32% of the stock is currently owned by institutional investors.

Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ AMPH) traded up 2.96% on Friday, reaching $18.45. The company’s stock had a trading volume of 576,650 shares. Amphastar Pharmaceuticals, Inc. has a 12 month low of $12.05 and a 12 month high of $21.75. The stock has a market cap of $843.85 million, a P/E ratio of 97.11 and a beta of 1.68. The firm’s 50-day moving average price is $17.39 and its 200-day moving average price is $15.99.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings data on Monday, May 8th. The company reported $0.03 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.06 by $0.03. The business had revenue of $56.67 million during the quarter, compared to analyst estimates of $63.74 million. Amphastar Pharmaceuticals had a return on equity of 2.69% and a net margin of 3.54%. The firm’s revenue for the quarter was down 4.5% compared to the same quarter last year. During the same period in the previous year, the business earned $0.12 EPS. On average, analysts forecast that Amphastar Pharmaceuticals, Inc. will post $0.40 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This report was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another domain, it was copied illegally and reposted in violation of U.S. & international copyright law. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/07/22/tudor-investment-corp-et-al-buys-8960-shares-of-amphastar-pharmaceuticals-inc-nasdaqamph-updated.html.

Several analysts have commented on the stock. Jefferies Group LLC set a $21.00 target price on shares of Amphastar Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, April 20th. Zacks Investment Research cut shares of Amphastar Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, May 16th. Finally, TheStreet raised shares of Amphastar Pharmaceuticals from a “c” rating to a “b-” rating in a research note on Monday, June 26th. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. Amphastar Pharmaceuticals currently has an average rating of “Buy” and an average price target of $20.14.

In other Amphastar Pharmaceuticals news, Director Michael A. Zasloff sold 15,000 shares of Amphastar Pharmaceuticals stock in a transaction dated Thursday, June 1st. The stock was sold at an average price of $17.01, for a total transaction of $255,150.00. Following the completion of the transaction, the director now owns 47,411 shares in the company, valued at approximately $806,461.11. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Jason B. Shandell sold 11,482 shares of Amphastar Pharmaceuticals stock in a transaction dated Wednesday, May 31st. The shares were sold at an average price of $16.92, for a total value of $194,275.44. Following the completion of the transaction, the director now owns 241,342 shares of the company’s stock, valued at approximately $4,083,506.64. The disclosure for this sale can be found here. Insiders sold a total of 43,982 shares of company stock valued at $735,850 in the last three months. Insiders own 11.10% of the company’s stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

Institutional Ownership by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Stock Ratings for Amphastar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.